SCHEMBL2328159

SCHEMBL2328159

C=CCc1cccc2cc(C(=O)Nc3ccc(C(=O)O)cc3)c(=O)oc12

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.85
RAB9A P51151 2/20 0.85
MAPT P10636 5/20 0.79
POLB P06746 3/20 0.78
MEN1 O00255 3/20 0.78
KMT2A Q03164 3/20 0.78
TDP1 Q9NUW8 2/20 0.78
PLEC Q15149 1/20 0.78
ALDH1A1 P00352 7/20 0.71
TP53 P04637 1/20 0.71
KDM4E B2RXH2 9/20 0.68
HSD17B10 Q99714 4/20 0.68
GAA P10253 1/20 0.61
MAOA P21397 1/20 0.59
MAOB P27338 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
PKM P14618 1/20 0.58
HPGD P15428 1/20 0.58
APEX1 P27695 1/20 0.58
PTPN7 P35236 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2331162 0.91 MAPT (0.85) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL14119286 0.88 MAPT (1.00) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL3880564 0.84 MAPT (0.77) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL3945435 0.83 MAPT (0.72) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL3278007 0.83 ALDH1A1 (0.73) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL4518987 0.82 MAPT (0.73) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL3884846 0.79 MAPT (0.68) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL2361446 0.77 MAPT (0.66) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL4389144 0.75 MAOA (1.00) NPC1RAB9AMAPTTP53MAOA
SCHEMBL3952682 0.70 MAPT (0.51) NPC1RAB9AMAPTPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160067257-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY THE WISTAR INSTITUTE (US) 2016-03-10 US disclosed
US-9234230-B2 Screening method and compounds for modulating telomerase activity THE WISTAR INSTITUTE (US) 2016-01-12 US disclosed
US-8377992-B2 TRBD-binding effectors and methods for using the same to modulate telomerase activity THE WISTAR INSTITUTE (US) 2013-02-19 US disclosed
US-20120309759-A1 Screening Method and Compounds for Modulating Telomerase Activity THE WISTAR INSTITUTE (US) 2012-12-06 US disclosed
WO-2011097600-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY THE WISTAR INSTITUTE (US) 2011-08-11 WO disclosed
US-20100160260-A1 TRBD-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity THE WISTAR INSTITUTE 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309759-A1 Screening Method and Compounds for Modulating Telomerase Activity TERT, TERB1, TERF2 NPC1 3713/4885RAB9A 3522/4885MAPT 2733/4885
US-20160067257-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY TERT, TERB1, TERF2 NPC1 3713/4885RAB9A 3522/4885MAPT 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.